Forward Pharma Operations ApS

Q: What is the CVR number of Forward Pharma Operations ApS?

Forward Pharma Operations ApS is registered with CVR / Virk under CVR 38757504.

Q: Where is Forward Pharma Operations ApS headquartered?

Forward Pharma Operations ApS's registered address is Strandvejen 125.

APSIn liquidationAdvertising protection

CVR 38757504Strandvejen 125, 2900 HellerupResearch and experimental development on natural sciences and engineering· NACE 7210Est. 2017 · 9 years old— employees

Overview

Forward Pharma Operations ApS is a Danish APS based in Hellerup, operating in the Research and experimental development on natural sciences and engineering sector. Incorporated in 2017, the company reported revenue of DKK 99.1k in its latest annual filing.

Revenue 2024

0.1M DKK

−82% vs 2023

EBITDA margin

−2,273.4 %

+4% vs 2023

Net profit 2024

-68.3M DKK

-6651% vs 2023

Key ratios

See full ratios →

80.1 %

Strong

Among the 30% highest rated companies in the industry

20202024

5.0×

Strong

Among the 30% highest rated companies in the industry

20202024

-19.6 %

Very weak

Among the 20% lowest rated companies in the industry

20202024

EBITDA — year on year

DKK thousands

Key figures

Annual report 2024

Revenue	0.1M DKK	-82%
EBITDA	-2.3M DKK	+4%
Net profit	-68.3M DKK	-6651%
Total assets	349.4M DKK	+16%
Equity	280M DKK	0%
Employees	—	—

Contact

Address

Strandvejen 125, 2900 Hellerup

Advertising protection

Active — opted out of marketing use

Risika for professionals

Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.

Visit risika.com

Financial development

In its most recent annual report (2024), Forward Pharma Operations ApS reported revenue of DKK 99.1k, a decrease of 82% on the year before. The figures on this page draw on 5 annual filings covering 2020 to 2024. The bottom line showed a net loss of DKK 68.3m, and the EBITDA margin stood at -2,273.4%.

At the end of 2024, equity financed 80.1% of the balance sheet, and current assets covered short-term debt 5 times. Forward Pharma Operations ApS is one of 2 companies registered under Research and experimental development on natural sciences and engineering in Denmark.

Financials

Revenue

DKK thousands

EBITDA

DKK thousands

Income statement

DKK thousands

Item	2024	2023	2022	2021	2020
Revenue	99	547	724	622	351
Staff expenses	-0	-0	-0	-0	-0
EBITDA	-2,254	-2,342	-7,895	-9,004	-8,158
Depreciation & amort.	-0	-0	-0	-0	-0
EBIT	-2,254	-2,342	-7,895	-9,004	-8,158
Net financials	-66,067	3,385	-19,127	-483	-1,951
Profit before tax	-68,320	1,043	-27,022	-9,487	-10,109
Tax	23	-0	-0	-0	-0
Net profit	-68,344	1,043	-27,022	-9,487	-10,109

Get a credit rating – not just the numbers

Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.

See the credit rating

Balance sheet

DKK thousands

Item	2024	2023	2022	2021	2020
Total assets	349,447	302,114	305,109	327,107	337,159
Equity	280,041	279,126	278,083	305,105	314,592
Long-term debt	0	0	0	0	0
Short-term debt	69,406	22,988	27,026	22,001	22,567
Total debt	69,406	22,988	27,026	22,001	22,567

Financial ratios

5-year trend

EBITDA margin

<−999 %

20202024

Equity ratio

80.1 %

Strong

Among the 30% highest rated companies in the industry

20202024

Return on equity

-24.4 %

Very weak

Among the 20% lowest rated companies in the industry

20202024

Net profit margin

<−999 %

Very weak

Among the 10% lowest rated companies in the industry

20202024

Asset turnover

0.00×

Weak

Among the 30% lowest rated companies in the industry

20202024

Debt / equity

0.25×

Strong

Among the 40% highest rated companies in the industry

20202024

Sector performance

26 of 28 ratios graded

28 financial ratios from the latest filing, each graded against companies in the same industry.

Profitability

Gross marginVery weak

Among the 10% lowest rated companies in the industry

The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.

Operating marginVery weak

Among the 10% lowest rated companies in the industry

EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.

Net profit marginVery weak

Among the 10% lowest rated companies in the industry

The profit for the year as a share of revenue — the company's ability to turn revenue into profit.

Return on equity (ROE)Very weak

Among the 20% lowest rated companies in the industry

Net profit as a percentage of equity — the return the owners earned on their invested capital this year.

Return on assets (ROA)Very weak

Among the 20% lowest rated companies in the industry

Net profit as a percentage of total assets — the return generated on the capital employed.

Return on net assets (RONA)Very weak

Among the 20% lowest rated companies in the industry

Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.

Basic earning power (BEP)Weak

Among the 40% lowest rated companies in the industry

EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.

Capacity ratioNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.

Liquidity

Current ratioStrong

Among the 30% highest rated companies in the industry

Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.

Quick ratioStrong

Among the 30% highest rated companies in the industry

Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.

Cash ratioWeak

Among the 30% lowest rated companies in the industry

Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.

Current assets to equityAverage

Around the average of companies in the same industry

Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.

Fixed assets to long-term capitalVery strong

Among the 10% highest rated companies in the industry

Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.

Cash conversion ratioVery weak

Among the 20% lowest rated companies in the industry

Cash flow relative to profit — the ability to convert reported profits into accessible cash.

Debt & solvency

Solidity ratioStrong

Among the 30% highest rated companies in the industry

Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.

Debt ratioStrong

Among the 30% highest rated companies in the industry

Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.

Debt to equityStrong

Among the 40% highest rated companies in the industry

Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.

Liabilities to equityStrong

Among the 40% highest rated companies in the industry

Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.

Income to debtVery weak

Among the 10% lowest rated companies in the industry

Profit relative to debt — the ability to create earnings while operating with debt.

EBITDA to debtWeak

Among the 40% lowest rated companies in the industry

EBITDA relative to debt — how much operating earnings are available to service the debt.

Interest coverageVery weak

Among the 20% lowest rated companies in the industry

The ability to pay the interest on the company's debt out of its earnings.

Interest rate on debtStrong

Among the 40% highest rated companies in the industry

Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.

Interest marginVery weak

Among the 20% lowest rated companies in the industry

The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.

Efficiency & development

Asset turnoverWeak

Among the 30% lowest rated companies in the industry

Revenue relative to total assets — the ability to generate revenue from the asset base.

Equity to contributed capitalVery strong

Among the 10% highest rated companies in the industry

Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.

One-year change in equityAverage

Around the average of companies in the same industry

The size of this year's increase or decrease in the company's equity.

One-year change in debtVery weak

Among the 10% lowest rated companies in the industry

The size of this year's increase or decrease in the company's debt.

Inventory turnoverNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.

Annual reports & filings

Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View PDF
Annual report 2023
Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
View PDF
Annual report 2022
Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
View PDF
Annual report 2021
Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
View PDF
Annual report 2020
Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
View PDF

People & ownership

Management

Actively employed in the business

Name	Role	Member since

Former (2)


CB Claus Bo Søndergaard Svendsen Chief Executive Officer	Chief Executive Officer	2017 – 2025
JM Jakob Mosegaard Larsen Liquidator	Liquidator	2025 – 2025

Board of directors

Non-executive oversight

No data on file.

Shareholders

Active legal owners

Shareholder	Type	Ownership	Votes	Registered
FORWARD PHARMA A/S	Company	100%	100%	2017

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.

One in three Danish companies experiences fraud

Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.

See the fraud module

Related companies

Company hierarchy

Forward Pharma A/S100%

Forward Pharma Operations ApS (this company)

Board network connections

Board members of Forward Pharma Operations ApS also hold positions in 17 other companies.

Person	Role here	Other companies
Jakob Mosegaard Larsen	Liquidator	16 companiesMany roles
Claus Bo Søndergaard Svendsen	Chief Executive Officer	1 company

Frequently asked questions

What is the CVR number of Forward Pharma Operations ApS?

Forward Pharma Operations ApS is registered with CVR / Virk under CVR 38757504.

What is the revenue of Forward Pharma Operations ApS?

Forward Pharma Operations ApS reported revenue of DKK 99.1k in 2024.

Where is Forward Pharma Operations ApS headquartered?

Forward Pharma Operations ApS's registered address is Strandvejen 125.